Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR

Francis Joseph Giles

Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR

Francis Joseph Giles

Medicine

Research output: Other contribution (Published) › Other contribution

Original language	English (Ireland)
Media of output	Meeting
Volume	116
Publication status	Published - 1 Nov 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@misc{fe4d2cc933f6417696142fa31c7f64f0,

title = "Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR",

author = "Giles, \{Francis Joseph\}",

year = "2010",

month = nov,

day = "1",

language = "English (Ireland)",

volume = "116",

type = "Other",

}